OBJECTIVE: To report race-based outcomes after radical prostatectomy (RP) in a cohort stratified by National Comprehensive Cancer Network (NCCN) risk category with updated follow-up. MATERIALS AND METHODS: Studies describing racial disparities in outcomes after RP are conflicting. We studied 15,993 white and 1634 African American (AA) pretreatment-naïve men who underwent RP at our institution (1992-2013) with complete preoperative and pathologic data. Pathologic outcomes were compared between races using appropriate statistical tests; biochemical recurrence (BCR) for men with complete follow-up was compared using multivariate models that controlled separately for preoperative and postoperative covariates. RESULTS: Very low- and low-risk AA men were more likely to have positive surgical margins (P <.01), adverse pathologic features (P <.01), and be upgraded at RP (P <.01). With a median follow-up of 4.0 years after RP, AA race was an independent predictor of BCR among NCCN low-risk (HR, 2.16; P <.001) and intermediate-risk (hazard ratio [HR], 1.34; P = .024) classes and pathologic Gleason score ≤ 6 (HR, 2.42; P <.001) and Gleason score 7 (HR, 1.71; P <.001). BCR-free survival for very low-risk AA men was similar to low-risk white men (P = .890); BCR-free survival for low-risk AA men was similar to intermediate-risk white men (P = .060). CONCLUSION: When stratified by NCCN risk, AA men with very low-, low-, or intermediate-risk prostate cancer who undergo RP are more likely to have adverse pathologic findings and BCR compared with white men. AA men with "low risk" prostate cancer, especially those considering active surveillance, should be counseled that their recurrence risks can resemble those of whites in higher risk categories.
OBJECTIVE: To report race-based outcomes after radical prostatectomy (RP) in a cohort stratified by National Comprehensive Cancer Network (NCCN) risk category with updated follow-up. MATERIALS AND METHODS: Studies describing racial disparities in outcomes after RP are conflicting. We studied 15,993 white and 1634 African American (AA) pretreatment-naïve men who underwent RP at our institution (1992-2013) with complete preoperative and pathologic data. Pathologic outcomes were compared between races using appropriate statistical tests; biochemical recurrence (BCR) for men with complete follow-up was compared using multivariate models that controlled separately for preoperative and postoperative covariates. RESULTS: Very low- and low-risk AA men were more likely to have positive surgical margins (P <.01), adverse pathologic features (P <.01), and be upgraded at RP (P <.01). With a median follow-up of 4.0 years after RP, AA race was an independent predictor of BCR among NCCN low-risk (HR, 2.16; P <.001) and intermediate-risk (hazard ratio [HR], 1.34; P = .024) classes and pathologic Gleason score ≤ 6 (HR, 2.42; P <.001) and Gleason score 7 (HR, 1.71; P <.001). BCR-free survival for very low-risk AA men was similar to low-risk white men (P = .890); BCR-free survival for low-risk AA men was similar to intermediate-risk white men (P = .060). CONCLUSION: When stratified by NCCN risk, AA men with very low-, low-, or intermediate-risk prostate cancer who undergo RP are more likely to have adverse pathologic findings and BCR compared with white men. AA men with "low risk" prostate cancer, especially those considering active surveillance, should be counseled that their recurrence risks can resemble those of whites in higher risk categories.
Authors: Matthew E Nielsen; Misop Han; Leslie Mangold; Elizabeth Humphreys; Patrick C Walsh; Alan W Partin; Stephen J Freedland Journal: J Urol Date: 2006-08 Impact factor: 7.450
Authors: Ricardo F Sanchez-Ortiz; Patricia Troncoso; Richard J Babaian; Josep Lloreta; Dennis A Johnston; Curtis A Pettaway Journal: Cancer Date: 2006-07-01 Impact factor: 6.860
Authors: Christian von Bodman; Mika P Matikainen; Luis Herran Yunis; Vincent Laudone; Peter T Scardino; Oguz Akin; Farhang Rabbani Journal: Urology Date: 2010-11 Impact factor: 2.649
Authors: Ian M Thompson; Richard K Valicenti; Peter Albertsen; Brian J Davis; S Larry Goldenberg; Carol Hahn; Eric Klein; Jeff Michalski; Mack Roach; Oliver Sartor; J Stuart Wolf; Martha M Faraday Journal: J Urol Date: 2013-05-21 Impact factor: 7.450
Authors: Gary D Grossfeld; David M Latini; Tracy Downs; Deborah P Lubeck; Shilpa S Mehta; Peter R Carroll Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Jayakrishnan Jayachandran; Lionel L Bañez; William J Aronson; Martha K Terris; Joseph C Presti; Christopher L Amling; Christopher J Kane; Stephen J Freedland Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: Michael S Leapman; Stephen J Freedland; William J Aronson; Christopher J Kane; Martha K Terris; Kelly Walker; Christopher L Amling; Peter R Carroll; Matthew R Cooperberg Journal: J Urol Date: 2016-06-25 Impact factor: 7.450
Authors: Stephen J Freedland; Adriana C Vidal; Lauren E Howard; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; William J Aronson Journal: Cancer Date: 2017-06-27 Impact factor: 6.860
Authors: Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni Journal: Cancer Date: 2017-04-24 Impact factor: 6.860
Authors: Adam B Weiner; Richard S Matulewicz; Jeffrey J Tosoian; Joseph M Feinglass; Edward M Schaeffer Journal: Urol Oncol Date: 2017-11-15 Impact factor: 3.498